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a b s t r a c t
In a phase II/III clinical trial intraperitoneal (i.p.) administration of a group C adenovirus vector (Ad5)
caused bowel adhesion formation, perforation and obstruction. However, we had found that i.p. group B,
in contrast to group C adenoviruses, did not cause adhesions in nude BALB/c ovarian cancer models,
prompting further investigation. Ex vivo, group B Ad11 caused lower inﬂammatory responses than Ad5
on BALB/c peritoneal macrophages. In vivo, i.p. Ad11 triggered short-term cytokine and cellular responses
equal to Ad5 in both human CD46-positive and -negative mice. In contrast, in a long-term study of
repeated i.p. administration, Ad11 caused no/mild, whereas Ad5 induced moderate/severe adhesions and
substantial liver toxicity accompanied by elevated levels of IFNγ and VEGF and loss of i.p. macrophages,
regardless of CD46 expression. It appears that, although i.p. Ad11 evokes immediate inﬂammation similar
to Ad5, repeated administration of Ad11 is better tolerated and long-term ﬁbrotic tissue remodelling is
reduced.
& 2013 Elsevier Inc. All rights reserved.
Introduction
New chemotherapeutics and advanced treatment regimens for
ovarian cancer resulted in a rise of the relative 5-year survival rate
of patients presenting at Fédération Internationale de Gynécologie
et d’Obstétrique (FIGO) stages I and II by 10–25% in the last 25
years (CRUK, 2013). In contrast, due to the development of
chemoresistance, current treatments for advanced disease (FIGO
III and IV) have yet to signiﬁcantly improve patient prognosis. The
use of gene- and virotherapy could present a means to overcome
this limitation. While systemic application of these approaches is
currently limited by low target infection, pre-existing immunity
and induction of inﬂammation, ovarian tumours remain largely
conﬁned to the peritoneal cavity, which allows regional, intraper-
itoneal (i.p.) administration and might permit the use of higher
treatment doses, due to lower systemic toxic effects.
Initial i.p. clinical trials employed adenovirus serotype 5 (Ad5)
as a gene delivery vector to restore wild-type p53 in p53-deﬁcient
tumours (Buller et al., 2002a, 2002b; Wolf et al., 2004), or
introduce the expression of enzymes that convert a non-toxic
prodrug into the active chemotherapeutic agent (Alvarez et al.,
2000; Hasenburg et al., 2001, 2000). Concurrently, conditionally
replicating adenoviruses (CRAd) for which replication and onco-
lysis was thought to be dependent on p53 deﬁciency of host cells
were evaluated (Vasey et al., 2002). However, ultimately, these
treatments demonstrated only limited clinical efﬁcacy. A lack of
the Ad5 entry receptors CAR (Bergelson et al., 1997) and integrins
αVβ3/5 (Wickham et al., 1993) has been proposed as one of the main
reasons for the failure of Ad5-based cancer gene therapy
(Hermiston, 2006; Zeimet and Marth, 2003). Indeed, CAR and
integrin expression on primary ovarian tumours is limited (Zeimet
et al., 2002) and loss of αVβ3 expression on ovarian cancer cells
restricts Ad5 transduction (Brüning et al., 2001). Neutralisation is
likely to be another reason for low efﬁcacy of Ad5-derived agents.
High prevalence of anti-Ad5 antibodies in serum from healthy
volunteers (Vogels et al., 2003) and in the ascitic ﬂuid of ovarian
cancer patients (Stallwood et al., 2000) has been demonstrated.
Furthermore, recent reports have shown that Ad5 virions can be
sequestered by non-target cells such as erythrocytes (Carlisle et al.,
2009) and platelets (Othman et al., 2007) through binding to CAR
on their cell surfaces.
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Apart from low transduction efﬁcacy, one of the major constraints
to successful i.p. application of Ad5-based therapies has been their
toxicity. Initially, local administration was thought to ameliorate
inﬂammatory responses in comparison to observations after systemic
administration of recombinant Ad5 (Raper et al., 2003). However,
while overall side-effects in clinical trials of i.p. Ad5 were mild (Buller
et al., 2002b; Wolf et al., 2004), a subsequent phase II/III clinical trial
of SCH58500 was terminated at interim analysis due to serious local
inﬂammatory responses such as bowel adhesions, perforation and
obstruction. Although the results of this trial were never formally
published, it was subsequently reported that much of the treatment
dose was detected in peritoneal macrophages (Zeimet and Marth,
2003). The central role of macrophages as mediators of the innate
inﬂammatory response against adenovirus has been demonstrated in
different animal models. In C57BL/6 mice, intravenous (i.v.) injection
of a non-replicating Ad5-derived vector prompted an immediate
inﬂammatory response characterised by dendritic cell (DC) and
macrophage-dependent expression of IL-6 and IL-12 (Zhang et al.,
2001). Further investigation in ex vivo splenocyte cultures revealed
that DCs and macrophages, but not lymphocytes, produced these
cytokines. Similarly, a study in male rhesus macaques (Macaca
mulatta) demonstrated increased serum IL-6 and IL-12 levels after
intraportal administration of Ad5 vectors and analysis of splenocytes
indicated strongest transgene expression in monocytes/macrophages
(Schnell et al., 2001). In regional delivery, previous studies in athymic
nude mice with ovarian tumour xenografts demonstrated long-term
inﬂammation and adhesion formation after i.p. wild-type Ad5
(Morrison et al., 2008, 2009). Adhesion formation was likely to be
caused by activation of the innate immune system through cellular
responses by macrophages and DCs. Overall, it appears that the
immediate response to Ad5, characterised by inﬂammatory cytokine
expression by macrophages, is similar across species and could be the
reason for the deleterious side-effects observed in the phase II/III
clinical trial of SCH58500 described above.
The use of adenovirus serotypes other than Ad5 might help to
overcome current obstacles to efﬁcient i.p. adenovirus virotherapy.
Ad11 is a group B adenovirus, that infects cells via the complement
regulatory receptor CD46 (Gaggar et al., 2003; Sirena et al., 2004;
Segerman et al., 2003). CD46 was demonstrated to be highly and
homogenously expressed on ovarian tumour samples (Bjørge et al.,
1997) and over-expressed on malignant in comparison to non-
transformed cells (Fishelson et al., 2003). In addition, neutralisation
of Ad11 should be lower than Ad5 as CD46, in contrast to CAR, was
found to not be expressed on human erythrocytes (Liszewski et al.,
1991), and, globally, the prevalence of antibodies against Ad11 appears
markedly lower than against Ad5 (Vogels et al., 2003; Nwanegbo et al.,
2004). Importantly, a previous study demonstrated inﬂammatory
signalling against Ad11 similar to Ad5 following i.v. injection into
mice (Stone et al., 2007). However, it remains unclear if this response
would be altered after i.p. application due to the different physiological
setting and primary target cells. In addition, preliminary observations
from in vivo experiments in our group had suggested that i.p. Ad11
caused less peritoneal inﬂammation than Ad5 (Nicola Green, unpub-
lished data). Hence, the studies described here sought to investigate
possible advantages to the use of Ad11 in comparison to Ad5 in terms
of reduced inﬂammatory stimulation in the peritoneal cavity.
Results
Cytokine responses of ex vivo murine macrophages towards Ad3, Ad5
or Ad11
Monocytes and macrophages constitute the most abundant cell
population in human peritoneal ﬂuid (Kubicka et al., 1996) and
appear to be pivotal in the recruitment of neutrophils to sites of
inﬂammation through cytokine signalling (Cahill and Redmond,
2008). While it has been reported that mesothelial cells, which are
the main functional constituent of the peritoneal lining, are equally
capable of cytokine production and concomitantly inﬂuencing
inﬂammatory responses (Mutsaers, 2002), selective depletion of
peritoneal F4-80 cells (a marker for murine macrophages (Austyn
and Gordon, 1981)) lead to markedly reduced CXC chemokine
production and prevented neutrophil inﬂux in an experimental
peritonitis model (Cailhier et al., 2005). These ﬁndings suggest a
central role for macrophages in the initiation of inﬂammatory
responses in the peritoneum. Therefore, an ex vivo macrophage
model of adenovirus infection was chosen to assess the immediate
peritoneal inﬂammatory response towards Ad5 and Ad11 in vitro.
Murine macrophages were obtained from BALB/c mice after induc-
tion of sterile peritonitis as previously described (Cash et al., 2008).
Initial experiments were designed to investigate the cytokine
response towards adenovirus over a 24 h time-course to determine
a time-point of strong cytokine expression and select representative
markers, which could be used in subsequent ELISA experiments.
Adherent murine macrophages were treated with Ad5 or vehicle,
supernatants collected at speciﬁed time-points and screened for the
concentrations of nine cytokines (IL-1β, IL-6, IL-10, IL-12, MIP-1β, MIP-
2, KC, RANTES and TNF-α), which have previously been shown to be
secreted after adenovirus stimulation (Zhang et al., 2001; Muruve
et al., 1999). While time-dependent changes of concentrations could
be observed for all cytokines IL-6, MIP-1β, KC and RANTES demon-
strated the most signiﬁcant differences between vehicle- and Ad5-
treated cells (Fig. 1A). Expression of IL-6 was 2-fold (po0.01), MIP-1β
3.5-fold (po0.001) and RANTES expression 10-fold (po0.001) higher
24 h after Ad5- in comparison to mock-treatment. In a preliminary
study, Ad11 was tested alongside Ad5 (Fig. 1B). Ad5 elicited signiﬁ-
cantly higher MIP-1β and RANTES concentrations than Ad11 (po0.01
and po0.001, respectively), while KC expression was signiﬁcantly
lower after Ad5 than Ad11 treatment (po0.05) 24 h after treatment.
Based on these ﬁndings RANTES, a chemokine that attracts
monocytes/macrophages and T cells in addition to stimulating T cell
maturation, was selected as a marker of inﬂammatory responses in
further ex vivo studies. Murine macrophages were treated with Ad5 or
Ad11 and the concentration of RANTES was measured in supernatants
collected 2, 8, 16 or 24 h after inoculation (Fig. 1C). A greater increase
in RANTES expression in response to Ad5-, in comparison to vehicle-
or Ad11-treatment, could be observed over the incubation period
leading to an 8-fold increased concentration in the cell supernatant
after 24 h (po0.001). Importantly, values measured in Ad11- did not
differ from mock-treated wells at any time-point. Ad3, a group B
adenovirus like Ad11, was used to investigate if these results were
common to adenoviruses of the same group (Fig. 1D). Interestingly,
while the differential stimulation by Ad5 and Ad11 was conﬁrmed,
Ad3 did not show decreased RANTES signalling. Instead, RANTES
concentrations were not signiﬁcantly different from Ad5- and higher
than mock-treated cells after 16 and 24 h of incubation (po0.05). This
observation suggests that inﬂammatory properties differ between
serotypes and are not necessarily shared bymembers of an adenovirus
group. Overall, these ex vivo studies suggested that i.p. administration
of Ad11-based treatments might not induce the same inﬂammatory
responses as observed after Ad5 application. While macrophages are
one of the dominant mediators of inﬂammatory reactions towards
infectious agents in the peritoneal cavity, the immune response in
the peritoneum is co-ordinated by a variety of cell types. Hence,
we decided to examine if these ex vivo results would correspond to
responses in vivo.
Short-term in vivo inﬂammatory responses to i.p. adenovirus
Previous studies demonstrated a strong inﬂammatory response
in the ﬁrst 24 h after intravenous injection of Ad5-derived vectors
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into C57BL/6 mice characterised by expression of cytokines like IL-
6 and IL-12 (Zhang et al., 2001). It was therefore apparent that
strong reactions would occur soon after i.p. adenovirus inoculation
and we hypothesised that these might determine detrimental
long-term effects. In vivo studies of i.p. Ad5 and Ad11 sought to
investigate two aspects of the intraperitoneal immune response.
First, the activation of the inﬂammatory response was analysed
through cytokine measurements in both blood and i.p. ﬂuid
samples. Second, the cellular response in terms of migration
patterns was examined by quantiﬁcation of neutrophil and macro-
phage numbers in the peritoneal cavity.
We ﬁrst investigated the timing and range of the inﬂammatory
response after i.p. Ad5 in BALB/c mice over a 24 h time-course
(study IP-1) to determine a time-point of strong response which
could be used in subsequent studies. The cellular response
(Fig. 2A) was characterised by decreased numbers of macrophages
after 4 h followed by an increase until 24 h to double that in
0 h samples. The neutrophil count appeared to be a two-phase
response, starting with an initial peak in cell numbers at 8 h,
followed by a nadir at 16 h and a second peak at 24 h. The
concentrations of nine cytokines (Fig. 2B) were assayed in perito-
neal and serum samples. Intraperitoneal levels of KC and MIP-2
peaked 2 h after i.p. Ad5, preceding the main neutrophil inﬂux,
in keeping with their reported roles as neutrophil chemokines
(Ramos et al., 2006). In contrast, levels of IL-1β, IL-6, IL-10, IL-12
(p40) MIP-1β, RANTES and TNF-α started to increase by 2 h, but did
not peak until 4–8 h and had a more sustained response heralding
the following inﬂux of macrophages. Serum levels of MIP-1β,
MIP-2 and KC rose more slowly than peritoneal levels, possibly
demonstrating that early production of cytokines is localised to
the peritoneal compartment. Overall, Fig. 2 shows that the serum
cytokine response has slower kinetics than that of the peritoneal
cavity and that cytokine levels are increased in different propor-
tions. From these results we decided to assess immediate inﬂam-
matory reactions 6 h after virus injection as a distinct decrease of
macrophages, marked increase of neutrophils and peaks of cyto-
kine expression were to be expected at this time-point.
Short-term comparison of Ad5 and Ad11
While CD46, the main receptor for Ad11 infection, is ubiquitously
expressed in humans, its murine equivalent is only expressed in
mouse testes (Inoue et al., 2003). It was therefore not clear whether
the differences between serotypes observed in the ex vivo experi-
ments were due to reduced Ad11 infection. Therefore, studies
comparing in vivo responses to i.p. Ad5 and Ad11 were performed
Fig. 1. Cytokine responses of peritoneal murine macrophages following ex vivo adenovirus treatment. Elicited peritoneal macrophages from Balb/c mice were incubated
ex vivowith (A) Ad5 (103 vp/cell) or vehicle (PBS) or with (B) Ad5 or Ad11 (103 vp/cell) and cytokine levels in supernatants at speciﬁed time-points analysed with a Bio-Plexs
system. Bars represent mean concentrations (n¼3) of accumulated cytokines and standard deviations. Analysis of temporal change of cytokine levels of Ad5-treated cells
was performed by one-way ANOVA with Dunett's multiple comparison test versus a control column (2 h time-point) (##po0.01). Time-points with signiﬁcant differences
between Ad5- and mock- or Ad11-treated cells were identiﬁed by unpaired t-tests (nnnpo0.001, nnpo0.01, npo0.05). Macrophages were incubated with (C) Ad5 or Ad11
(103 vp/cell), vehicle or LPS/IFNγ (100/20 ng/ml) or with (D) Ad3, Ad5 or Ad11 (103 vp/cell) or vehicle. RANTES levels in supernatants at speciﬁed time-points were measured
by ELISA. Bars represent mean concentrations (n¼3) of accumulated RANTES and standard deviations. Statistical analysis per time-point was performed by one-way ANOVA
with Tukey's multiple comparison test (ns¼not signiﬁcant, nnnpo0.001, nnpo0.01, npo0.05; # symbols on top of bars represent p-values versusmock-treated cells (ns¼not
signiﬁcant, ###po0.001, ##po0.01, #po0.05); OOR¼out of range).
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in CD46-transgenic mice of C57/BL6 background (Oldstone et al.,
1999) (study IP-2). A following experiment (study IP-3) also included
non-transgenic littermates of the CD46-transgenic animals and
ordinary C57/BL6 mice in the Ad11 treatment arm, in order to
investigate, if results observed with Ad11 in IP-2 were due to CD46
expression or represented immune responses speciﬁc to the in vivo
setting in comparison to the ex vivo experiments.
Cytokine levels (IL-1β, IL-6, IL-10, IL-12(p40), IFNγ, MCP-1, RANTES
and TNFα) of IP-2 and IP-3 were analysed in both serum and i.p.
lavage samples. Notably, there was a marked increase of expression
of all cytokines in all adenovirus- in comparison to mock-treated
animals (data not shown). Surprisingly, Ad11 did show stimulation of
IL-6 and RANTES to levels equal to or above Ad5 (Fig. 3A), in contrast
to data obtained in the ex vivo experiments. Furthermore, this effect
was not restricted to the CD46-transgenic animals, but was also
observed in the non-transgenic littermates and wild-type C57/
BL6 mice.
Cellular responses were investigated through analysis of numbers
of neutrophils and macrophages. The microphotographs are repre-
sentative of immunocytochemistry slides from these experiments
(Fig. 3B). More cells stained positive for the vehicle- than for the
virus-treated animals when labelling macrophages, while there were
fewer cells positive for the neutrophil-speciﬁc antibody. Fig. 3C
depicts the amount of macrophages or neutrophils as a percentage
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of the whole cell population. As indicated by the microphotographs
macrophage and neutrophil numbers were signiﬁcantly lower or
higher in adenovirus- in comparison to mock-treated animals,
respectively. No difference in the cellular response towards Ad5
and Ad11 was found.
In summary, it appeared that i.p. Ad11 caused short-term
inﬂammatory stimulation similar to Ad5. Hence, results observed
in the ex vivomodel did not appropriately reﬂect the intraperitoneal
reaction to Ad11. Interestingly, the response of non-transgenic
and wild-type C57BL/6 mice was equal to CD46-transgenic ani-
mals suggesting that CD46 expression was inconsequential in this
setting.
Long-term in vivo inﬂammatory responses to i.p. adenovirus
These ﬁndings raised concerns about the feasibility of using
Ad11 clinically as a means of avoiding the immune responses
generated by Ad5. However, previously unpublished studies had
suggested that i.p. Ad11 caused less long-term toxicity than Ad5
(Nicola Green, unpublished data). We, therefore, decided to
examine whether the similar acute inﬂammation caused by Ad5
and Ad11 would ultimately also lead to the same long-term
toxicities previously observed with Ad5 (Morrison et al., 2008).
This study had shown that three i.p. adenovirus administrations of
51010 vp/mouse with intervals of 3 days between injections
caused long-term inﬂammatory sequelae and the onset of adhe-
sion formation after 18 days (Morrison et al., 2008). In the present
experiments virus doses were reduced to 11010 vp of Ad5 or
Ad11 per mouse in order to minimise animal distress. 18 days after
the ﬁrst injection animals were sacriﬁced and peritoneal cavities
examined for signs of inﬂammation and adhesion formation in
addition to analysis of cytokine levels and cellular responses.
Experiments were performed in CD46-transgenic mice (study
IP-4) and wild-type C57/BL6 mice (study IP-5) to investigate if
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CD46 expression played a role in long-term toxicity after adeno-
virus treatment.
Fig. 4A shows photographs from experiment IP-5 representa-
tive for the appearance of peritoneal cavities of mice treated with
Ad5, Ad11 or vehicle. Notably, while organs of animals treated
with Ad11 were equal in appearance to vehicle-treated mice, gross
changes in liver architecture (blunting of liver edges and reduced
size possibly due to liver capsule ﬁbrosis/acute hepatitis), enlarge-
ment of the spleen and matting of organs were observed in Ad5-
treated animals. Furthermore, in some Ad5-treated animals the
peritoneal lining appeared inﬂamed and red. All animals were
scored for signs of inﬂammation as reported previously (Morrison
et al., 2008) prior to unblinding of assessors (Fig. 4B). Mock-
treatment was well tolerated in all animals. Ad11 treatment
caused mild inﬂammatory symptoms in ﬁve of six of the CD46-
transgenic animals (IP-4) and no symptoms in non-transgenic C57/
BL6 mice (IP-5). In contrast, Ad5 induced markedly greater
long-term pathologic effects in the form of moderate to severe
adhesions and profound changes in gross liver pathology in both
CD46-transgenic and non-transgenic animals.
Measurement of cytokine levels (IL-6, IL-10, IL-12(p40), IFNγ,
MCP-1, RANTES and VEGF) of peritoneal ﬂuid and serum samples
demonstrated little difference between treatment groups for most
cytokines (data not shown). However, peritoneal ﬂuid from Ad11-
treated CD46-transgenic mice (IP-4) showed signiﬁcant elevation
of IL-12 in comparison to mock-treatment (po0.05) and of
RANTES in comparison to mock- (po0.01) and Ad5-treatment
(po0.05). In contrast, Ad5-treated animals expressed signiﬁcantly
higher levels of IFNγ and VEGF than both Ad11- or mock-treated
animals (po0.05 or po0.01) (Fig. 4C). While the same pattern
could be observed in the CD46-negative C57BL/6 mice (IP-5), these
results did not reach signiﬁcance (data not shown).
Analysis of levels of neutrophils and macrophages in peritoneal
lavage samples demonstrated no cells positive for NIMP (data not
shown), suggesting very low levels of free neutrophils in the cavity
at this time-point regardless of treatment type. Notably however,
levels of F4/80-positive macrophage were signiﬁcantly reduced
in Ad5- in comparison to mock- or Ad11-treated mice (po0.001)
(Fig. 4D). Similarly, the total amount of free cells in the cavity was
signiﬁcantly lower after Ad5 treatment in both CD46-transgenic
(po0.001) and non-transgenic animals (po0.05).
Discussion
Previous studies had demonstrated that Ad5 treatment of ovarian
tumour xenografts in nude mice provoked strong long-term inﬂam-
matory reactions in the form of adhesion formation (Morrison et al.,
2008, 2009). Similar observations had led to the suspension of a
phase II/III clinical trial of i.p. gene therapy with an Ad5-based vector
(Zeimet and Marth, 2003) at interim analysis (Stephen Chang,
unpublished personal communication). However, previous in vivo
experiments in our group had suggested that i.p. Ad11 caused less
peritoneal toxicity than Ad5 treatment (Nicola Green, unpublished
data). Hence, the experiments presented in this study investigated
the inﬂammatory response towards different adenovirus serotypes in
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Fig. 4. Long-term in vivo pathologic effects after i.p. adenovirus. CD46-transgenic (IP-4) or non-transgenic C57BL/6 mice (IP-5) (both n¼6) were injected i.p. with Ad5 or
Ad11 (1010 vp/mouse) or vehicle three times with an interval of 72 h between injections. 18 days after the ﬁrst injection animals were sacriﬁced and after preparation of
samples for cytokine and cell analysis, peritoneal cavities were examined for signs of inﬂammation and adhesion formation. (A) Photographs show representative peritoneal
cavities from IP-5 after treatment with Ad5, Ad11 or vehicle. (B) Animals of IP-4 and IP-5 were scored for signs of inﬂammation as reported previously (Morrison et al., 2008)
(mild: light ﬁlmy adhesions or inﬂammation, moderate: denser adhesions, still able to dissect out bowel loops, severe: dense adhesions causing bowel matting, dilatation or
subacute obstruction, unable to dissect out bowel loops; data-points represent the number of animals for each scoring group per treatment). (C) Cytokine levels in i.p. lavage
samples were analysed using a Bio-Plexs system (measurements from CD46-transgenic mice (IP-4); bars and error bars represent the mean of single measurements for each
treated animal and standard deviations; statistical analysis by one-way ANOVA with Bonferroni post-tests to compare pairs of treatments (nnpo0.01, npo0.05)).
(D) Numbers of macrophages (F4/80) and neutrophils (NIMP) in the peritoneal ﬂuid were counted on cytospins of peritoneal lavage ﬂuids after immunocytochemistry and
are expressed as the percentage of the whole cell population (bars and error bars represent the mean of triplicate countings for each treated animal and standard deviations;
statistical analysis by one-way ANOVA with Bonferroni post-tests to compare pairs of treatments (nnnpo0.001, nnpo0.01)).
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order to identify possible advantages of the use of Ad3 or Ad11 in
comparison to Ad5 in future virotherapy of ovarian cancer.
An ex vivo model of peritoneal inﬂammation using peritoneal
macrophages from BALB/c mice demonstrated up to 8-fold higher
expression of the inﬂammatory cytokine RANTES after Ad5 in
comparison to Ad11 treatment, while values of Ad11- did not differ
from mock-treated cells. This suggests that i.p. administration of
Ad11 might not induce the same inﬂammatory responses as have
previously been observed after Ad5 application (Morrison et al.,
2009). Interestingly, although Ad3 and Ad11 both belong to adeno-
virus group B, Ad3, in contrast to Ad11, stimulated cytokine
signalling which was not signiﬁcantly different from Ad5 (group
C). This suggests that the immediate cytokine response following
adenovirus stimulation is serotype-speciﬁc and not shared among
members of an adenovirus group. However, Ad3 has been classiﬁed
as a subspecies B1 adenovirus, while Ad11 belongs to subspecies B2
(Wadell et al., 1980) and diverging use of uptake receptors (Desmo-
glein2 for Ad3 and CD46 for Ad11) (Wang et al., 2011) has been
demonstrated, which might lead to the observed differential
stimulation of inﬂammatory signalling in macrophages.
Due to the promising results of low inﬂammatory stimulation
after Ad11, in comparison to Ad5 treatment, in the ex vivo model,
animal studies were designed to investigate this differential immune
response further. As mice only express CD46 in the testes (Inoue
et al., 2003), CD46-transgenic mice with a human-like expression
pattern (Oldstone et al., 1999) and non-transgenic C57BL/6 mice were
used in these studies. Notably, short-term experiments, where
animals were sacriﬁced 6 h after treatment, revealed that i.p. Ad11
did show stimulation of cytokines to levels equal to or in some cases
even signiﬁcantly above Ad5, in contrast to observations ex vivo. This
is in accordance with previously published data of cytokine expres-
sion after i.v. Ad5 or Ad11 in CD46-transgenic mice (Stone et al.,
2007). However, it was surprising to observe increased inﬂammatory
signalling after i.p. Ad11 in the non-transgenic mice, as the ex vivo
model would have predicted a lower response towards Ad11 than
Ad5. While it is possible, that these differing data are due to the
different mouse strains used in the ex vivo (BALB/c) and in vivo
(C57BL/6) model, it appears that the ex vivo study of isolated
macrophages was not able to represent the more complex peritoneal
in vivo environment. This suggests that the immediate intraperito-
neal inﬂammatory reaction is not only triggered by macrophages, but
develops through the interplay with other resident cell populations
like the mesothelial lining cells as well as chemotacticly attracted
immune cells, such as neutrophils. Indeed, a signiﬁcant difference
between adenovirus- and mock-treated animals regarding the cel-
lular components of their i.p. ﬂuid was observed 6 h after treatment.
The number of macrophages was signiﬁcantly lower, while the
number of neutrophils was signiﬁcantly higher in Ad5- or Ad11- in
comparison to mock-treated mice, in both CD46-transgenic and non-
transgenic animals. This signiﬁcant decrease in the number of
macrophages in the peritoneal cavity followed the pattern, which
has previously been described as the ‘macrophage disappearance’
reaction. Previous studies had demonstrated that macrophages
adhere to the peritoneal wall at sites of injury and after challenge
with inﬂammatory agents like LPS or, indeed, Herpes simplex virus,
possibly due to chemokine signalling from mesothelial cells (Barth
et al., 1995; Cheong et al., 2001). Furthermore, monocytes and
macrophages, after contact with the pathogen, could withdraw from
the peritoneal cavity in order to home to adjacent lymph nodes for
further immunological signalling and antigen presentation (Bellingan
et al., 1996). The signiﬁcant increase in the amount of neutrophils has
previously been described (Cailhier et al., 2005; Knudsen et al., 2002)
and is one of the hallmarks of the early reaction to intraperitoneal
inﬂammatory stimulation.
While the short-term in vivo experiments revealed that Ad5
and Ad11 had similar inﬂammatory short-term effects, previous
studies in murine i.p. xenograft models had suggested that i.p.
Ad11 caused less long-term inﬂammatory toxicity and adhesion
formation than Ad5 (Nicola Green, unpublished data). To further
investigate this observation, studies were designed, based on the
protocols used in experiments that had previously shown strong
long-term toxicities after i.p. Ad5 administration (Morrison et al.,
2008). Notably, Ad5 induced signiﬁcantly more severe long-term
pathologic effects in the form of adhesions and liver toxicity in
all animals, in comparison to Ad11. It was found that this was
accompanied by signiﬁcantly higher levels of IFNγ and VEGF expres-
sion and a signiﬁcantly reduced number of macrophages and, indeed,
total cell number, in the i.p. ﬂuid of Ad5- in comparison to Ad11- or
vehicle-treated animals.
The adhesion formation after traumatic interventions in the
peritoneal cavity continues to be a great concern in the clinic and
research into clarifying the mechanisms involved is ongoing.
Studies have revealed a complex system of cellular and molecular
events. It appears that adhesions are often the result of an
inordinate wound repair involving mesothelial cells, ﬁbroblasts,
monocytes, macrophages and neutrophils, whose localisation and
function are mutually regulated by cytokine and chemokine
signalling (Cahill and Redmond, 2008; White et al., 2011). During
this process, cell numbers of resident macrophages in the perito-
neal ﬂuid drop due to adherence to the peritoneum (Cheong et al.,
2001). Ultimately, a pathologically altered ﬁbrin/plasmin-ratio,
leads to profuse depositions of ﬁbrin, which can grow to become
well-organized, vascularised and innervated tissues (Sulaiman
et al., 2002). One of the key-players of these processes appears
to be VEGF, which has been implicated in tissue remodelling and
wound healing processes. In the process of adhesion formation its
effect of increasing vascular permeability and concurrent deposi-
tion of ﬁbrin-rich matrices appears to be of particular importance
(Cahill and Redmond, 2008). Hence, the increased VEGF and
diminished macrophage levels observed in the long-term studies
described here appear to indicate that similar tissue remodelling
processes occur after Ad5- but not Ad11-treatment. The presence
of large surfaces with adhesive properties might explain the
generally decreased cell numbers in Ad5-treated animals.
Previous reports investigating the liver toxicity of Ad5 and Ad11
after i.v. injection into CD46-transgenic mice demonstrated that
Ad11, in contrast to Ad5, did not induce increased serum levels
of liver enzyme alanine aminotransferase (ALT) on day 3 after
administration (Shashkova et al., 2009). It was reasoned that this
might be due to a lack of interaction of Ad11 with FX and the
consequent absence of hepatocyte infection. Furthermore, the
authors could show that predosing of animals with Ad5, but not
Ad11, lead to increased hepatocyte transgene expression after
subsequent administration of an Ad5-derived vector, concluding
that Ad11, in contrast to Ad5, did not kill liver-resident Kupffer
cells. These ﬁndings might explain the absence of long-term
i.p. toxicities after Ad11 treatment. First, the severe hepatotoxicity
after Ad5 administration, which was also observed in the present
study, might cause secondary inﬂammatory effects in the perito-
neal cavity, unbalancing its regular inﬂammatory responses. Sec-
ond, if the toxic effect of Ad5 on Kupffer cells is also occurring in
resident peritoneal macrophages, the absence of this pivotal cell
type and its inﬂuence on the inﬂammatory signalling cascade
might lead to aberrant cytokine expression from mesothelial cells
and neutrophils and subsequent inordinate inﬂammatory effects
resulting in symptoms of adhesion formation as observed in the
present studies. Hence, while Ad11 caused short-term responses
similar to Ad5, the absence of hepatotoxicity and the availability of
i.p. macrophages to control inﬂammatory responses prevented
excessive long-term toxicity.
The present i.p. in vivo studies revealed that the use of Ad11, in
contrast to Ad5, might have a major advantage in future applications
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of adenovirus virotherapy of ovarian cancer. If these ﬁndings are
translatable to the human setting, patient safety would be consider-
ably increased.
Materials and methods
Adenoviruses
Wild-type adenoviruses serotype 3, 5 and 11p were purchased
from the Native Antigen Company. Absence of endotoxins in virus
batches was veriﬁed using Limulus amoebocyte lysate-assays
(Lonza). Virus particles (vp) were quantiﬁed using the Quant-
iT™ PicoGreens assay kit (Invitrogen) for double-stranded DNA
assuming 1 mg/ml of DNA is equivalent to 2.71010 vp (Murakami
and McCaman, 1999). Virus dilutions were prepared in TRIS-EDTA-
buffer (TE)/0.5% Sodium dodecyl sulphate (SDS) and incubated
at 56 1C for 30 min. A dilution series of bacteriophage λ DNA
prepared in the same medium served as a standard curve. 50 ml of
sample or standard curve dilution were dispensed in wells of a
black 96 half-well microplate and 50 ml of PicoGreens reagent
(Invitrogen; diluted 1:200 in TE) added. After incubating at room
temperature (RT) for 2 min ﬂuorescence was measured in a Wallac
1420 Victor2 multilabel counter (PerkinElmer) at an excitation and
emission wavelength of 485 nm and 535 nm, respectively. All virus
batches used for experiments comparing Ad5 and Ad11 demon-
strated equal amounts of infectious particles (data not shown).
Generation and treatment of elicited murine peritoneal macrophages
Elicited murine peritoneal macrophages were generated as
previously described (Cash et al., 2008) and kindly provided by
Professor David Greaves, Dunn School of Pathology, University of
Oxford. Brieﬂy, BALB/c mice were injected i.p. with Bio-Gel P100
polyacrylamide beads (Bio-Rad) in PBS (2% w/v). After 4 days mice
were sacriﬁced and peritonea lavaged with PBS containing
2 mmol/l EDTA. Cells were pelleted (200 g, 5 min, 4 1C) and
resuspended in OptiMEM (Invitrogen) and plated into 6-well
tissue culture plates (1106/well). After incubation for 2 h at
37 1C, 5% CO2 non-adherent cells were removed by three PBS
washes and macrophages treated with virus (103 vp per cell), PBS
or lipopolysaccharide (LPS) (100 ng/ml) (Sigma-Aldrich)/interferon
gamma (IFNγ) (20 ng/ml) (Peprotech). After incubation for up to
24 h supernatants were collected.
ELISA and multiplex suspension array (Bio-Plexs) for cytokine
quantiﬁcation
ELISAs for RANTES cytokine levels were performed as per
manufacturer's instructions (Quantikines, R&D Systems). Absor-
bance was measured at 450 nm/595 nm using a Wallac 1420 Victor2
multilabel counter (PerkinElmer). RANTES concentration of samples
was extrapolated from a standard curve of optical densities of
known amounts of recombinant murine RANTES using a 4-
parameter logistic curve-ﬁt. Simultaneous assessment of multiple
cytokines in serum or cell supernatants was performed using Bio-
Plexs assays (Bio-Rad). Labelling and assay analysis were per-
formed according to manufacturer's instructions except that beads
and detection antibody were diluted 2 that recommended.
Animal studies
Studies involving laboratory animals (IP-1–5) were conducted
under licence in accordance with the UK Home Ofﬁce Animals
(Scientiﬁc Procedures) Act 1986. BALB/c (IP-1) and C57/BL6 (IP-3
and IP-5) mice were obtained from Biomedical Services Oxford or
Harlan Laboratories. CD46-transgenic mice (IP-2–4) expressing all
four major isoforms of human CD46 stably backcrossed onto the C57/
BL6 background were a kind gift from Michael Oldstone (Scripps
Research Institute, La Jolla) (Oldstone et al., 1999; Yannoutsos et al.,
1996). Mice were housed in temperature and humidity-controlled
conditions (20–22 1C) at Biomedical Services, John Radcliffe Hospital,
Oxford (IP-1 and 5) or KCL Biological Services Unit (BSU), London (IP-
2–4). Mice were given free access to sterile tap water and formulated
diets, housed in environmentally-enriched, individually ventilated
cages with no more than 6 mice per cage, and exposed to a 12 h
light-dark cycle. For all animal studies participating investigators
were blinded to the type of treatment until after ﬁnal analysis of
cytokine and cellular responses.
Short-term i.p. infection and sample preparation
Immune competent mice were injected i.p. with 500 ml of PBS
containing 51010 (IP-1 and 2) or 2.51010 (IP-3) vp of Ad5 or
Ad11 or no virus. Mice were monitored for acute toxicity for
30 min and after 6 h mice were sacriﬁced by cervical dislocation.
After conﬁrmation of death, a small hole in the abdominal wall
and parietal peritoneum was made and 2 ml PBS instilled. The
mouse was gently agitated and i.p. wash ﬂuid aspirated with a
Pasteur pipette. Blood was taken by cardiac puncture and allowed
to clot at RT for 30 min, centrifuged at 10,000g for 5 min and
serum aspirated. The i.p. wash was centrifuged at 200g for 2 min,
the supernatant collected and its volume measured. The cell pellet
was resuspended in PBS at an equal volume to the previously
removed supernatant for each sample. 50 ml aliquots of cells were
spun onto polylysine coated microscope slides (VWR) using a Cytos-
pin2 (Shandon) at 1250 rpm for 2 min and ﬁxed with Shandon Cell
Fixx (Thermo).
Long-term i.p. infection, sample preparation and adhesion scoring
Long-term studies (IP-4 and 5) to examine the effect of i.p. Ad5
and Ad11 were designed according to previously published meth-
ods (Morrison et al., 2008). Immune competent mice were injected
i.p. with 250 ml of virus storage buffer (vsb) containing 11010 vp
of Ad5 or Ad11 or no virus three times with an interval of 72 h.
After each injection mice were monitored for acute toxicity for
30 min. 18 days after the ﬁrst injection mice were sacriﬁced and
samples prepared as described above. In addition, peritoneal
cavities were opened and organs and peritoneum inspected and
scored for symptoms of inﬂammation and adhesion formation as
previously reported (Morrison et al., 2008). Investigators were
blinded to the type of treatment at this stage.
Immunocytochemistry
Immunocytochemical staining was performed using the ABC-
alkaline phosphatase (ABC-AP) kit (Vector). After each incubation
step at RT, slides were washed twice with PBS. Cytospin samples
were soaked in PBS and incubated for 60 min with a 1:100 dilution
of rabbit serum (VECTOR) in PBS before incubation with rat anti-
F4/80 antibody (AbD Serotec), rat anti-NIMP-14 (abcam) or an
isotype control (abcam) at 2.5 mg/ml for 60 min. Samples were
then incubated with mouse adsorbed, biotinylated anti-rat anti-
body (Vector) for 30 min and with Vectastain ABC-AP reagent for
further 30 min. Vector Red AP substrate was prepared in Tris–HCl
pH 8.2 and incubated on samples for 30 min. Samples were then
washed with water, counterstained with Hematoxylin (Shandon)
for 10 min, dehydrated with ethanol, cleared in Histoclear (RA
Lamb) and mounted in p-Xylene-bis-N-pyridinium bromide (DPX)
mounting medium (RA Lamb). Slides were left to dry overnight
before examination. Three high power ﬁelds per slide were
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imaged (20 objective lens) on a Nikon Eclipse 80i microscope
with a Nikon DS-5M camera using Nikon Imaging Software AR 3.0.
On each image the number of all cells and positively stained cells
was counted.
Data and statistical analyses
Data was processed using Microsoft Ofﬁce Excel 2007 (Micro-
soft Corporation) or GraphPad Prism4 Software (GraphPad Soft-
ware, Inc.). Statistical analysis was performed using GraphPad
Prism4. The identities of statistical tests employed are indicated
in ﬁgure legends, where applicable.
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